Formations of, Acquisitions by, and Mergers of Bank Holding Companies, 1094-1095 [2024-00166]
Download as PDF
<![CDATA[
1094
Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices
(NAMs), to reduce, refine or replace
vertebrate animal testing and provide
information of equivalent or better
scientific quality and relevance for
assessing risks of injury to health or the
environment.
ADDRESSES: The docket for this action,
identified by docket identification (ID)
number EPA–HQ–OPPT–2023–0627, is
available online at https://
www.regulations.gov. Additional
instructions for visiting the docket,
along with more information about
dockets generally, is available at https://
www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT: For
technical information contact: Renee
Beardslee, New Chemical Division
(7405M), Office of Pollution Prevention
and Toxics, Environmental Protection
Agency, 1200 Pennsylvania Ave. NW,
Washington, DC 20460–0001: telephone
number: (202) 564–8787; email address:
beardslee.renee@epa.gov.
For general information contact: The
TSCA-Hotline, ABVI-Goodwill, 422
South Clinton Ave., Rochester, NY
14620; telephone number: (202) 554–
1404; email address: TSCA-Hotline@
epa.gov.
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
I. Does this action apply to me?
This action is directed to the public
in general. This notice may be of
specific interest to persons who are or
may be interested in risk assessments of
new chemical substances under TSCA
(e.g., submitters of TSCA 5 notices,
industry, non-governmental
organizations (NGOs), and academia).
Since other entities may also be
interested, the Agency has not
attempted to describe all the specific
entities that may be affected by this
action.
II. What action is the Agency taking?
EPA is announcing the availability of
a new decision framework for use by the
New Chemicals Division (NCD) of the
Office of Pollution Prevention and
Toxics (OPPT) for identification of eye
irritation or corrosion hazards for new
chemical substances based on
prioritization of reproducible, humanrelevant data. The document supports
EPA’s efforts to develop NAMs that do
not require vertebrate animal testing and
furthers the agency’s commitment to
reduce and replace the use of vertebrate
animals in the testing of chemical
substances and mixtures.
TSCA section 4(h)(2)(A) directs EPA
to ‘‘promote the development and
implementation of alternative test
methods and strategies to reduce, refine,
or replace vertebrate animal testing and
VerDate Sep<11>2014
16:38 Jan 08, 2024
Jkt 262001
provide information of equivalent or
better scientific quality and relevance
for assessing risks of injury to health or
the environment.’’
To incorporate alternative test
methods and strategies, or NAMs, data
for eye irritation and corrosion hazard
identification into the new chemicals
program risk assessment process, NCD
developed a framework for new
chemical risk assessments that
prioritizes reproducible, humanrelevant in vitro data. The Framework is
based upon existing peer-reviewed
literature, accepted Organization for
Economic Cooperation and
Development (OECD) test guidelines,
and other existing accepted risk
assessment approaches.
NCD is responsible for conducting
risk assessments for new chemical
substances submitted under TSCA
section 5 authority. NCD expects
multiple benefits from the incorporation
of this proposed Framework in its
assessment including: (1) progress
towards fulfilling TSCA section 4(h)(2)
statutory requirements; (2) transparency
for stakeholders regarding EPA’s process
of hazard identification of eye irritation
and corrosion for new chemical
submissions; (3) clear scientific
rationale for identification of eye
irritation and corrosion hazards for
human health assessors leading to
improved consistency across final new
chemical risk assessments; and (4) use
of the most reproducible, humanrelevant scientific data for decisionmaking.
III. Does this Framework impose
binding requirements?
This document is not binding on the
Agency or any outside parties, and the
Agency may depart from it where
circumstances warrant and without
prior notice. While EPA has made every
effort to ensure the accuracy of the
discussion in the Framework, the
obligations of EPA and the regulated
community are determined by statutes,
regulations, or other legally binding
documents. In the event of a conflict
between the discussion in the
Framework document and any statute,
regulation, or other legally binding
document, the Framework document
will not be controlling.
IV. Is this Framework subject to the
Paperwork Reduction Act (PRA)?
This action does not contain any new
or revised information collections or
burden subject to additional OMB
approval under the PRA, 44 U.S.C. 3501
et seq. Burden is defined in 5 CFR
1320.3(b). Information collection
activities contained in the TSCA new
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
chemicals program are already approved
by OMB under the PRA and are
assigned OMB Control No. 2070–0038
(EPA ICR No. 1188.14).
Authority: 15 U.S.C. 2604 et seq.
Dated: January 3, 2024.
Michal Freedhoff,
Assistant Administrator, Office of Chemical
Safety and Pollution Prevention.
[FR Doc. 2024–00169 Filed 1–8–24; 8:45 am]
BILLING CODE P
FEDERAL DEPOSIT INSURANCE
CORPORATION
Sunshine Act Meetings
9:30 a.m. on Friday,
January 5, 2024.
PLACE: The meeting was held via video
conference on the internet.
STATUS: Closed.
MATTERS TO BE CONSIDERED: The Special
Review Committee of the Federal
Deposit Insurance Corporation met to
consider matters related to the
Corporation’s corporate activities within
its authority to act on behalf of the
Federal Deposit Insurance Corporation.
In calling the meeting, the Special
Review Committee determined, by the
unanimous vote of Director Jonathan P.
McKernan and Director Michael J. Hsu
(Acting Comptroller of the Currency),
that Corporation business required its
consideration of the matters which were
to be the subject of this meeting on less
than seven days’ notice to the public;
that no earlier notice of the meeting was
practicable; that the public interest did
not require consideration of the matters
in a meeting open to public observation;
and that the matters could be
considered in a closed meeting by
authority of subsections (c)(2) and (c)(4)
of the ‘‘Government in the Sunshine
Act’’ (5 U.S.C. 552b(c)(2) and (c)(4)).
CONTACT PERSON FOR MORE INFORMATION:
Requests for further information
concerning the meeting may be directed
to Debra A. Decker, Executive Secretary
of the Corporation, at 202–898–8748.
TIME AND DATE:
Dated: January 5, 2024.
Federal Deposit Insurance Corporation.
James P. Sheesley,
Assistant Executive Secretary.
[FR Doc. 2024–00333 Filed 1–5–24; 4:15 pm]
BILLING CODE 6714–01–P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
E:\FR\FM\09JAN1.SGM
09JAN1
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than February 7, 2024.
A. Federal Reserve Bank of Atlanta
(Erien O. Terry, Assistant Vice
President) 1000 Peachtree Street NE,
Atlanta, Georgia 30309; Comments can
also be sent electronically to
Applications.Comments@atl.frb.org]:
1. Eureka Investor Group, Inc.,
Birmingham, Alabama; to become a
bank holding company by acquiring
Eureka Homestead Bancorp, Inc., a
savings and loan holding company, and
thereby indirectly acquire Eureka
Homestead, a savings association
subsidiary, both of Metairie, Louisiana.
In addition, Eureka Homestead Bancorp,
Inc. will convert from a savings and
loan holding company to a bank holding
company in connection with Eureka
Homestead’s conversion from a savings
association to a national bank.
Board of Governors of the Federal
Reserve System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2024–00166 Filed 1–8–24; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
16:38 Jan 08, 2024
Jkt 262001
GOVERNMENT ACCOUNTABILITY
OFFICE
Request for Medicare Payment
Advisory Commission (MedPAC)
Nominations
U.S. Government
Accountability Office.
ACTION: Request for letters of
nomination and resumes.
AGENCY:
The Balanced Budget Act of
1997 established the Medicare Payment
Advisory Commission (MedPAC) and
gave the Comptroller General
responsibility for appointing its
members. The U.S. Government
Accountability Office (GAO) is now
accepting nominations for MedPAC
appointments that will be effective in
May 2024. Nominations should be sent
to the email address listed below.
Acknowledgement of receipt will be
provided within a week of submission.
DATES: Letters of nomination and
resumes should be submitted no later
than February 9, 2024, to ensure
adequate opportunity for review and
consideration of nominees prior to
appointment.
SUMMARY:
Submit letters of
nomination and resumes to
MedPACappointments@gao.gov.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Gregory Giusto at (202) 512–8268 or
giustog@gao.gov if you do not receive an
acknowledgement or need additional
information. For general information,
contact GAO’s Office of Public Affairs at
(202) 512–4800.
Authority: 42 U.S.C. 1395b–6.
Gene L. Dodaro,
Comptroller General of the United States.
[FR Doc. 2024–00181 Filed 1–8–24; 8:45 am]
BILLING CODE 1610–02–P
1095
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)–
RFA–PS–24–040, Understanding Infant
Feeding Preferences, Practices, and
Outcomes for Mothers and other Parents
with HIV in the United States.
Date: March 28, 2024.
Time: 10 a.m.–5 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Seraphine Pitt Barnes, Ph.D., M.P.H.,
C.H.E.S., Scientific Review Officer,
National Center for HIV, Viral Hepatitis,
STD, and TB Prevention, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H24–6,
Atlanta, Georgia 30329–4027.
Telephone: (770) 488–6115; Email:
SPittBarnes@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–00214 Filed 1–8–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Medicare & Medicaid
Services
Notice of Closed Meeting
Pursuant to 5 U.S.C. 1009(d), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, CDC, pursuant to Public Law
92–463. The grant applications and the
discussions could disclose confidential
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
[Document Identifiers: CMS–10398 #43, #45,
and #48]
Medicaid and Children’s Health
Insurance Program (CHIP) Generic
Information Collection Activities:
Proposed Collection; Comment
Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
E:\FR\FM\09JAN1.SGM
09JAN1
]]>Agencies
[Federal Register Volume 89, Number 6 (Tuesday, January 9, 2024)]
[Notices]
[Pages 1094-1095]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00166]
=======================================================================
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and Mergers of Bank Holding
Companies
The companies listed in this notice have applied to the Board for
approval,
[[Page 1095]]
pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et
seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other
applicable statutes and regulations to become a bank holding company
and/or to acquire the assets or the ownership of, control of, or the
power to vote shares of a bank or bank holding company and all of the
banks and nonbanking companies owned by the bank holding company,
including the companies listed below.
The public portions of the applications listed below, as well as
other related filings required by the Board, if any, are available for
immediate inspection at the Federal Reserve Bank(s) indicated below and
at the offices of the Board of Governors. This information may also be
obtained on an expedited basis, upon request, by contacting the
appropriate Federal Reserve Bank and from the Board's Freedom of
Information Office at https://www.federalreserve.gov/foia/request.htm.
Interested persons may express their views in writing on the standards
enumerated in the BHC Act (12 U.S.C. 1842(c)).
Comments regarding each of these applications must be received at
the Reserve Bank indicated or the offices of the Board of Governors,
Ann E. Misback, Secretary of the Board, 20th Street and Constitution
Avenue NW, Washington, DC 20551-0001, not later than February 7, 2024.
A. Federal Reserve Bank of Atlanta (Erien O. Terry, Assistant Vice
President) 1000 Peachtree Street NE, Atlanta, Georgia 30309; Comments
can also be sent electronically to [email protected]]:
1. Eureka Investor Group, Inc., Birmingham, Alabama; to become a
bank holding company by acquiring Eureka Homestead Bancorp, Inc., a
savings and loan holding company, and thereby indirectly acquire Eureka
Homestead, a savings association subsidiary, both of Metairie,
Louisiana. In addition, Eureka Homestead Bancorp, Inc. will convert
from a savings and loan holding company to a bank holding company in
connection with Eureka Homestead's conversion from a savings
association to a national bank.
Board of Governors of the Federal Reserve System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2024-00166 Filed 1-8-24; 8:45 am]
BILLING CODE P
